R. Stahel

Publications598
h-index73
Citations21,970
Highly Influential Citations675
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Peters
  • 437 Publications • 27,268 Citations
  • W. Weder
  • 799 Publications • 22,780 Citations
  • E. Felip
  • 859 Publications • 58,090 Citations
  • R. Rosell
  • 1,141 Publications • 54,010 Citations
  • Publications
  • Influence
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera…
View on PubMed
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
TLDR
Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ER CC1-positive tumors do not.
View on PubMed
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
TLDR
It is emphasised that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre, and a three step pre-treatment assessment is proposed.
View on Publisher
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
TLDR
A total of 35 experts met to address several questions on non-small-cell lung cancer in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease.
View on PubMed
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International…
View on PubMed
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
TLDR
A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease.
View on PubMed
CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells.
TLDR
It is reported that CD24, a mucin-type glycosylphosphatidylinositol-linked cell surface molecule on human neutrophils, pre B lymphocytes, and many tumors can promote binding to P-selectin, and the role of CD24 is established as a novel ligand for P- selectin on tumor cells.
View on PubMed
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
TLDR
The data demonstrate that quantification of plasma DNA is an accurate technique amenable to standardization, which might complement current methods for the prediction of patient survival and might be considered for evaluation in large prospective studies.
View on PubMed
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
TLDR
Recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas are focused on.
View on PubMed
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
View on Elsevier
...
...